Beam's revenue is collaboration income from pharma partners — not sales of an approved drug.
↓ scroll to read
✦ The bottom line
Beam's Q1 2026 revenue of $31.7 million was up sharply from $7.5M a year earlier. But it's all collaboration revenue — payments from partners like Pfizer and Apellis for hitting research milestones. Beam has zero approved drugs and won't until 2027 at the earliest.
↓ the brief below
✦ Teach me
Collaboration revenue vs product sales
Biotech companies often have two very different revenue lines. Collaboration revenue is what a partner like Pfizer pays Beam to do research — milestone payments, upfront fees, and reimbursed costs. It can swing dramatically year to year. Product sales are what comes in when a drug is on the market and being prescribed. Beam has only the first kind. The whole investment thesis is getting to the second kind.
Wall Street calls this
Pre-commercial biotech
A 4x jump in collaboration revenue is fine — but it doesn't tell you the company is closer to selling actual drugs. The clinical readouts do.
The top line · latest quarter
$32
M
Q1 2026 revenue was $31.7M, up from $7.5M a year earlier — but every dollar of it is collaboration income, not product sales.
Source · 10-Q · Condensed Consolidated Statements of Operations (revenue) · Q1 2026 · Filed May 7, 2026
If revenue isn't the story, what is? For Beam, the real growth metric is the pipeline — specifically how many programs are in the clinic, how advanced they are, and how the data has read out. Q1 2026's most important development wasn't on the income statement: it was the announcement of a 60 mg optimal biological dose for BEAM-302, the lead program.
The real growth · pipeline progress
5
programs
Five active programs in or near the clinic: BEAM-302 (AATD lung disease), risto-cel (sickle cell), BEAM-304 (PKU), BEAM-301 (GSDIa), and BEAM-103 (anti-CD117 antibody).